Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus
Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus
复制标题
DOI：
10.1017/s0007114515002408
复制
发表时间：
2015-09-14
影响因子：
3.6
通讯作者：
Yamamoto, Norio
中科院分区：
文献类型：
--
作者：
Sugimura, Tetsu;Takahashi, Hitoshi;Yamamoto, Norio
乳酸乳球菌。lactis JCM5805已被证明是一种罕见的乳酸菌，可以激活小鼠和人类的浆细胞样树突细胞。在这项研究中，我们进行了一项随机安慰剂对照双盲实验，以评估其对冬季流感样疾病发病机制的影响。共有213名志愿者被分为两组，一组每天饮用由乳酸菌JCM5805制成的酸奶，另一组饮用安慰剂饮料，持续10周。在JCM5805组中，与安慰剂组相比，“咳嗽”和“发烧”（定义为流感样疾病的主要症状）的累积发生率天数显着减少。此外，在灭活的人流感病毒A/H1N1 （A/PR/8/34）存在下培养志愿者外周血单个核细胞。与安慰剂组相比，A/H1N1诱导的ifn - α在JCM5805组中有升高的趋势，并且在摄入期后，由A/H1N1诱导的ifn - α诱导的抗病毒因子干扰素刺激基因15 （ISG15）在JCM5805组中明显高于安慰剂组。这些结果表明，摄入JCM5805能够通过增强ifn - α介导的对流感病毒的反应来预防流感样疾病的发病机制。
Lactococcus lactis ssp. lactis JCM5805 has been shown to be a rare lactic acid bacterium that can activate plasmacytoid dendritic cells in both murine and human species. In this study, we carried out a randomised placebo-controlled double-blind experiment to evaluate its effect on the pathogenesis of influenza-like illness during the winter season. A total of 213 volunteers were divided into two groups, which received either yogurt made with L. lactis JCM5805 or a placebo beverage daily for 10 weeks. In the JCM5805 group, the cumulative incidence days of 'cough' and 'feverishness', which are defined as major symptoms of an influenza-like illness, were significantly decreased compared with the placebo group. In addition, peripheral blood mononuclear cells prepared from volunteers were cultured in the presence of inactivated human influenza virus A/H1N1 (A/PR/8/34). IFN-alpha elicited by A/H1N1 tended to be higher in the JCM5805 group compared with the placebo group, and an IFN-alpha-inducible antiviral factor, interferon-stimulated gene 15 (ISG15), elicited by A/H1N1 was significantly higher in the JCM5805 group compared with the placebo group after the intake period. These results suggest that intake of JCM5805 is able to prevent the pathogenesis of an influenza-like illness via enhancement of an IFN-alpha-mediated response to the influenza virus.